20:10 ETAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetesprnewswire·Apr 26 at 07:12 PMATXS0.00%FBT+1.05%
Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual ReportTip Ranks·Mar 24 at 09:35 AMATXS0.00%
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | COSM Stock NewsStockTitan·Feb 24 at 03:30 AMCOSM+4.19%XHE+1.37%
Axtria releases U.S. Incentive Compensation Benchmarking Study 2026 to aid life sciences, enhancing performance.Unusual Whales·Feb 19 at 08:28 AMATXS0.00%CS精准医-4.32%
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM ConferenceMarket Beat·Jan 13 at 01:04 AMATXS0.00%BCRX-1.14%
17:12 ET Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXSprnewswire·Jan 7 at 04:13 PMBCRX-1.14%ATXS0.00%
